Ligand Pharmaceuticals Incorporated — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012. Unless otherwise noted, amounts are in millions of dollars. Ligand is a biotechnology company focused on drug discovery, early-stage development, and partnering; its portfolio includes royalty-generating assets and CyDex’s Captisol formulation technology.
Financial performance
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Total revenue | $5.742 | $7.463 | $11.378 | $11.359 |
| Operating loss | $(1.730) | $(0.810) | $(2.495) | $(2.292) |
| Loss from continuing operations | $(4.066) | $(0.914) | $(4.553) | Income $9.114 |
| Net income (loss) | $(2.267) | $(0.914) | $(0.883) | Income $9.118 |
| Operating cash flow | Not provided separately | Not provided separately | $(1.101) | $(7.134) |
- Q2 revenue fell 23% year over year, while six-month revenue was essentially unchanged. Six-month royalties rose to $6.043 million from $4.165 million, principally from Promacta and Captisol-licensed products; material sales declined to $2.332 million from $4.034 million, attributed to Captisol purchase timing.
- Q2 continuing-operations loss widened, with higher interest expense and a $1.153 million increase in the contingent value rights (CVR) liability among the factors. Six-month 2011 results included a $13.444 million income-tax benefit from a valuation-allowance release; this was not repeated in 2012.
- Q2 2012 net loss included $1.799 million of discontinued-operations income, mainly a gain from revised estimates related to the prior Avinza sale. The comparable six-month gain was $3.670 million.
- Q2 operating margin was approximately negative 30% (operating loss divided by revenue); the filing does not state a gross margin.
Balance sheet, debt and liquidity
- At June 30, cash and cash equivalents were $8.885 million, short-term investments $1.500 million, and restricted cash and investments $1.341 million. Current assets were $21.096 million and current liabilities $30.419 million, leaving negative working capital of $9.323 million.
- Total assets were $104.594 million, total liabilities $86.142 million, and stockholders’ equity $18.452 million. Accumulated deficit was $682.654 million.
- Debt included $1.500 million drawn on the revolving line and $28.017 million in notes payable ($5.806 million current and $22.211 million long-term). The term loan bears fixed rates of 8.64% and 8.9012%, matures August 2014, and requires interest-only payments through March 2013; the revolver matures March 2013 and is cash-collateralized.
- Six-month cash increased $1.844 million to $8.885 million. Investing activities provided $3.703 million, mainly from short-term investment sales, while financing activities used $0.758 million. The company paid $4.549 million to CVR holders during the period.
Changes, outlook and material items
- Management said available cash, investments, and expected royalty, license, and milestone receipts should fund anticipated operating and capital requirements for at least 12 months. It cited possible discretionary expense reductions if revenues or cash flows fall short, but cautioned that additional financing might be needed and might not be available on acceptable terms.
- There is no quantified revenue or earnings guidance. Management identified Promacta royalty growth, Captisol sales, product approvals, and potential license and milestone revenue as expected sources of support.
- After quarter-end, Onyx received FDA accelerated approval for Kyprolis in July 2012. Ligand is entitled to tiered royalties of 1.5%–3%, milestones, and Captisol material revenue. GSK submitted Promacta applications for hepatitis C use in May; priority review was announced in July. These developments post-date the reporting period.
- The CyDex CVR liability was $13.7 million at June 30. A former shareholder representative disputed calculations of payments for the first two quarters of 2011 and alleged a breach of a debt limitation; Ligand disagreed, and arbitration could follow if the dispute is not resolved.
- Other obligations include $22.156 million of undiscounted operating lease payments, partly offset by expected sublease receipts, and Captisol supply and research-investment commitments. The company also remains contingently liable to Organon if King defaults on Avinza-related payments; the recorded liability was $14.756 million.
- Risk factors include reliance on partner products and royalties, sole-source Captisol supply, clinical and regulatory uncertainty, patent protection and competition, financing needs, and potential CVR or other disputes. Management reported that controls associated with a previously identified material weakness were tested and operating effectively for the quarter ended June 30, 2012.
Most important facts to verify
- Whether Promacta, Kyprolis, and other partnered products generate royalties and Captisol sales at the pace management anticipates.
- Whether cash resources and forecast receipts cover obligations despite negative working capital, debt service, lease costs, and CVR payments.
- The resolution and potential financial impact of the CyDex CVR dispute and remaining milestone-linked payments.
- Whether Kyprolis’s accelerated approval translates into sustained commercial sales; the filing notes that approval was based on response rate and survival benefit had not been demonstrated.
- Whether Captisol supply remains reliable and whether current and future patent rights protect the revenue stream.